Journal of Internal Medicine Concepts & Practice ›› 2023, Vol. 18 ›› Issue (04): 301-304.doi: 10.16138/j.1673-6087.2023.04.019
• Review article • Previous Articles Next Articles
KE Yuya, GONG Yanchun(
)
Received:2022-11-08
Online:2023-08-30
Published:2024-01-09
CLC Number:
KE Yuya, GONG Yanchun. Research progress of cardiovascular damage in primary aldosteronism[J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(04): 301-304.
| [1] |
Haze T, Hirawa N, Yano Y, et al. Association of aldo-sterone and blood pressure with the risk for cardiovascular events after treatments in primary aldosteronism[J]. Atherosclerosis, 2021, 324: 84-90.
doi: 10.1016/j.atherosclerosis.2021.03.033 URL |
| [2] |
Hundemer GL, Vaidya A. Primary aldosteronism diagnosis and management[J]. Endocrinol Metab Clin North Am, 2019, 48(4): 681-700.
doi: 10.1016/j.ecl.2019.08.002 URL |
| [3] |
Monticone S, Sconfienza E, D’Ascenzo F, et al. Renal damage in primary aldosteronism: a systematic review and meta-analysis[J]. J Hypertens, 2020, 38(1): 3-12.
doi: 10.1097/HJH.0000000000002216 pmid: 31385870 |
| [4] |
Conn JW, Louis LH. Primary aldosteronism, a new clinical entity[J]. Ann Intern Med, 1956, 44(1): 1-15.
doi: 10.7326/0003-4819-44-1-1 pmid: 13275846 |
| [5] |
Cheng CJ, Sung CC, Wu ST, et al. Novel KCNJ5 mutations in sporadic aldosterone-producing adenoma reduce Kir3.4 membrane abundance[J]. J Clin Endocrinol Metab, 2015, 100(1): E155-E163.
doi: 10.1210/jc.2014-3009 URL |
| [6] |
Fernandes-Rosa FL, Daniil G, Orozco IJ, et al. A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism[J]. Nat Genet, 2018, 50(3): 355-361.
doi: 10.1038/s41588-018-0053-8 pmid: 29403012 |
| [7] |
Perez-Rivas LG, Williams TA, Reincke M. Inherited forms of primary hyperaldosteronism: new genes, new phenotypes and proposition of a new classification[J]. Exp Clin Endocrinol Diabetes, 2019, 127(2/3): 93-99.
doi: 10.1055/a-0713-0629 URL |
| [8] |
Daniil G, Fernandes-Rosa FL, Chemin J, et al. CACNA1H mutations are associated with different forms of primary aldosteronism[J]. EBioMedicine, 2016, 13: 225-236.
doi: 10.1016/j.ebiom.2016.10.002 URL |
| [9] |
Fernandes-Rosa FL, Giscos-Douriez I, Amar L, et al. Different somatic mutations in multinodular adrenals with aldosterone-producing adenoma[J]. Hypertension, 2015, 66(5): 1014-1022.
doi: 10.1161/HYPERTENSIONAHA.115.05993 pmid: 26351028 |
| [10] | Nishimoto K, Tomlins SA, Kuick R, et al. Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands[J]. Proc Natl Acad Sci U S A, 2015, 112(33): E4591-E4599. |
| [11] |
Wannachalee T, Turcu AF. Primary aldosteronism: a continuum from normotension to hypertension[J]. Curr Cardiol Rep, 2021, 23(8): 105.
doi: 10.1007/s11886-021-01538-8 pmid: 34196827 |
| [12] |
Abdel Ghafar MT. An overview of the classical and tissue-derived renin-angiotensin-aldosterone system and its genetic polymorphisms in essential hypertension[J]. Steroids, 2020, 163: 108701.
doi: 10.1016/j.steroids.2020.108701 URL |
| [13] |
Gao X, Yamazaki Y, Tezuka Y, et al. Pathology of aldo-sterone biosynthesis and its action[J]. Tohoku J Exp Med, 2021, 254(1): 1-15.
doi: 10.1620/tjem.254.1 URL |
| [14] |
van der Heijden CDCC, Smeets EMM, Aarntzen EHJG, et al. Arterial wall inflammation and increased hematopoietic activity in patients with primary aldosteronism[J]. J Clin Endocrinol Metab, 2020, 105(5): E1967-E1980.
doi: 10.1210/clinem/dgz306 URL |
| [15] |
Rossi GP, Maiolino G. Excess arterial damage in hyperaldosteronism[J]. Hypertension, 2019, 74 (3): 502-504.
doi: 10.1161/HYPERTENSIONAHA.119.12395 pmid: 31352816 |
| [16] |
Monticone S, D’Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldo-steronism compared with essential hypertension: a systematic review and meta-analysis[J]. Lancet Diabetes Endocrinol, 2018, 6(1): 41-50.
doi: 10.1016/S2213-8587(17)30319-4 URL |
| [17] |
Ohno Y, Sone M, Inagaki N, et al. Prevalence of cardiovascular disease and its risk factors in primary aldosteronism[J]. Hypertension, 2018, 71(3): 530-537.
doi: 10.1161/HYPERTENSIONAHA.117.10263 URL |
| [18] |
Sukor N. Primary aldosteronism: from bench to bedside[J]. Endocrine, 2012, 41(1): 31-39.
doi: 10.1007/s12020-011-9553-3 pmid: 22042487 |
| [19] |
Meng Z, Dai Z, Huang K, et al. Long-term mortality for patients of primary aldosteronism compared with essential hypertension[J]. Front Endocrinol (Lausanne), 2020, 11: 121.
doi: 10.3389/fendo.2020.00121 URL |
| [20] |
Andrea Grillo, Lucia Salvi, Coruzzi P, et al. Sodium intake and hypertension[J]. Nutrients, 2019, 11(9): 1970.
doi: 10.3390/nu11091970 URL |
| [21] | Kronenberg H, Melmed S, Polonsky K, et al. Williams textbook of endocrinology[M]. 11th ed. Philadelphia, PA: Saunders, 2007: 1452-1463. |
| [22] | Sang M, Fu Y, Wei C, et al. Comparison of biomarkers of endothelial dysfunction and microvascular endothelial function in patients with primary aldosteronism and essential hypertension[J]. J Renin Angiotensin Aldosterone Syst, 2021, 22(1): 1470320321999491. |
| [23] |
Concistrè A, Petramala L, Bonvicini M, et al. Comparisons of skin microvascular changes in patients with primary aldosteronism and essential hypertension[J]. Hypertens Res, 2020, 43(11): 1222-1230.
doi: 10.1038/s41440-020-0475-4 |
| [24] |
Lottspeich C, Köhler A, Czihal M, et al. Atherosclerotic burden and arterial stiffness are not increased in patients with milder forms of primary aldosteronism compared to patients with essential hypertension[J]. Horm Metab Res, 2021, 53(3): 178-184.
doi: 10.1055/a-1326-2164 pmid: 33440431 |
| [25] |
Choudhary MK, Värri E, Matikainen N, et al. Primary aldosteronism: higher volume load, cardiac output and arterial stiffness than in essential hypertension[J]. J Intern Med, 2021, 289(1): 29-41.
doi: 10.1111/joim.v289.1 URL |
| [26] |
Pimenta E, Gordon RD, Ahmed AH, et al. Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism[J]. J Clin Endocrinol Metab, 2011, 96(9): 2813-2820.
doi: 10.1210/jc.2011-0354 URL |
| [27] | Huang X, Yu S, Xiao H, et al. Comparison of clinical features between primary aldosteronism and essential hypertension in Chinese patients[J]. Int J Endocrinol, 2021, 2021: 6685469. |
| [28] |
Wu Q, Hong M, Xu J, et al. Diurnal blood pressure pattern and cardiac damage in hypertensive patients with primary aldosteronism[J]. Endocrine, 2021, 72(3): 835-843.
doi: 10.1007/s12020-021-02606-3 pmid: 33474712 |
| [29] |
Wachtel H, Cerullo I, Bartlett EK, et al. Long-term blood pressure control in patients undergoing adrenalectomy for primary hyperaldosteronism[J]. Surgery, 2014, 156(6): 1394-1402.
doi: 10.1016/j.surg.2014.08.021 URL |
| [30] |
Ahmed S, Hundemer GL. Benefits of surgical over medical treatment for unilateral primary aldosteronism[J]. Front Endocrinol (Lausanne), 2022, 13: 861581.
doi: 10.3389/fendo.2022.861581 URL |
| [31] |
Satoh F, Ito S, Itoh H, et al. Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism[J]. Hypertens Res, 2020, 44(4): 464-472.
doi: 10.1038/s41440-020-00570-5 |
| [32] |
Rakugi H, Ito S, Itoh H, et al. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension[J]. Hypertens Res, 2019, 42(12): 1932-1941.
doi: 10.1038/s41440-019-0314-7 pmid: 31554937 |
| [33] |
Ravid JD, Laffin LJ. Effects of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, on cardiovascular disease, chronic kidney disease, and blood pressure[J]. Curr Cardiol Rep, 2022, 24(10): 1251-1259.
doi: 10.1007/s11886-022-01750-0 pmid: 35925515 |
| [34] |
Hundemer GL, Curhan GC, Yozamp N, et al. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism[J]. Lancet Diabetes Endocrinol, 2018, 6(1): 51-59.
doi: 10.1016/S2213-8587(17)30367-4 URL |
| [35] |
Nomura M, Kurihara I, Itoh H, et al. Association of cardiovascular disease risk and changes in renin levels by mineralocorticoid receptor antagonists in patients with primary aldosteronism[J]. Hypertens Res, 2022, 45(9): 1476-1485.
doi: 10.1038/s41440-022-00960-x |
| [36] |
Kallistratos MS, Pittaras A, Theodoulidis I, et al. Adverse effects of mineralocorticoid receptor antagonist administration[J]. Curr Pharm Des, 2018, 24(46): 5537-5541.
doi: 10.2174/1381612825666190222144359 URL |
| [1] | JIANG Yiran, WANG Weiqing. Research progress on molecular mechanism of primary aldosteronism [J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(04): 261-265. |
| [2] | LAI Liqin, GONG Yanchun. Research progress of chronic kidney injury in primary aldosteronism [J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(03): 211-214. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
